Transcriptomic effects of progesterone and mifepristone in the cycling endometrium. Transcriptomic effects of progesterone and mifepristone in the cycling endometrium

Mifepristone is an antagonist of the progesterone receptor in clinical use. Here, we explored the effects of mifepristone alone, and the effect of progesterone after the dose of mifepristone, on the transcriptomic signature in endometria from cycling women. Overall design: We obtained total RNA from endometrial biopsies taken 7 days after the LH maximum in consecutive cycles. In each cycle, women were treated with mifepristone alone, progesterone alone, a combination of both, or placebo.